Recent Updates
Recently added Catalysts
VNDA Positive Sentiment Score: 75/100

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

Tuesday, May 27, 2025 1 min read
Key Takeaway: Vanda Pharmaceuticals Inc. announced its inclusion in the 2025 ASCP Annual Meeting in Scottsdale, Arizona, where they will present research on Bysanti™, an atypical antipsychotic. The presentation will focus on pharmacokinetic results comparing Milsaperidone and Iloperidone. If approved, Bysanti™ is anticipated to enter the market in 2026, with a path for prolonged exclusivity extending into the 2040s.

Market Sentiment Analysis

POSITIVE FACTORS

  • Vanda Pharmaceuticals is presenting new pharmacokinetic research at a prestigious annual meeting.
  • The potential approval of Bysanti™ could lead to market availability in 2026.
  • Exclusivity and pending patents may protect Bysanti™ until the 2040s.

Full Press Release Details

WASHINGTON, May 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held in Scottsdale, Arizona, from May 27 through May 30, 2025.
The following will be presented:
Presentation Title: "Pharmacokinetic Results of Single-Dose and Multiple-Dose Bioequivalence Studies of Milsaperidone and Iloperidone Immediate-Release Oral Tablets"
Poster Presentation Session: II
Presenter: Sean R. Chadwick, PhD, Clinical Development
Bysanti™ is a new chemical entity that belongs in the class of atypical antipsychotic drugs. If approved, Bysanti™ could be available for sale in the US in 2026. Bysanti™ is believed to achieve its therapeutic effect by interacting with a host of neurotransmitter receptors in the brain, including the alpha-adrenergic receptor, serotonin receptors and dopamine receptors. Exclusivity, including pending patent applications, could extend into the 2040s.
About Vanda Pharmaceuticals Inc.
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
Jim Golden/Jack Keleher/Dan Moore
Collected Strategies
SOURCE Vanda Pharmaceuticals Inc.

21 %

more press release views with

Frequently Asked Questions

Where will the ASCP Annual Meeting 2025 take place?

The ASCP Annual Meeting 2025 will be in Scottsdale, Arizona.

Who is presenting at the ASCP Annual Meeting?

Sean R. Chadwick, PhD, will present at the meeting.

What is Bysanti™?

Bysanti™ is an atypical antipsychotic drug pending approval.

When might Bysanti™ be available for sale?

Bysanti™ could be available for sale in the US in 2026.

What receptors does Bysanti™ interact with?

Bysanti™ interacts with various neurotransmitter receptors in the brain.

Tags: VNDA Viatris Investor Conferences Healthcare Vanda Pharmaceuticals Bysanti ASCP Annual Meeting pharmacokinetic studies
Last updated: May 27, 2025